Multiple trials and research have proven that NAC combined with trastuzumab would increase the pCR rate for HER2-positive patients.[34] The NOAH trial investigated the curative effects of 1-year NAC in 235 HER2-positive LABC or inflammatory BC patients after dividing them into 2 groups randomly, with 1 group treated with only NAC and another combined trastuzumab. The gene discussed is ERBB2; the disease is breast cancer.